M. DiGiovanna

发表

Quantitative assessment Ki-67 score for prediction of response to neoadjuvant chemotherapy in breast cancer

D. Rimm, Jason R. Brown, M. DiGiovanna, 2014, Laboratory Investigation.

Durvalumab (MEDI4736) concurrent with nab-paclitaxel and dose dense doxorubicin cyclophosphamide (ddAC) as neoadjuvant therapy for triple negative breast cancer (TNBC).

L. Pusztai, G. Chung, A. Chagpar, 2018 .

Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer

M. Reiss, D. Zelterman, G. Chung, 2007, Breast Cancer Research and Treatment.

In vitro and in vivo Effects of Combination of Trastuzumab (Herceptin) and Tamoxifen in Breast Cancer

G. Mor, M. DiGiovanna, I. Ocal, 2005, Breast Cancer Research and Treatment.

Neoadjuvant trastuzumab induces apoptosis in primary breast cancers

S. Hilsenbeck, R. Schiff, Jenny C. Chang, 2005, Nature Clinical Practice Oncology.

Impact of financial burden of cancer on survivors' quality of life.

L. Pusztai, S. Evans, A. Chagpar, 2014, Journal of oncology practice.

Mutation based treatment recommendations from next generation sequencing data: a comparison of web tools

L. Pusztai, V. Bossuyt, C. Hatzis, 2016, Oncotarget.

Active signaling by HER-2/neu in a subpopulation of HER-2/neu-overexpressing ductal carcinoma in situ: clinicopathological correlates.

C. Howe, P. Chu, D. Stern, 2002, Cancer research.

Association of LN Evaluation with Survival in Women Aged 70 Years or Older With Clinically Node-Negative Hormone Receptor Positive Breast Cancer

L. Wilson, L. Pusztai, C. Hatzis, 2017, Annals of Surgical Oncology.

Does lymph node status influence adjuvant therapy decision-making in women 70 years of age or older with clinically node negative hormone receptor positive breast cancer?

L. Wilson, L. Pusztai, G. Chung, 2017, American journal of surgery.

Activation state-specific monoclonal antibody detects tyrosine phosphorylated p185neu/erbB-2 in a subset of human breast tumors overexpressing this receptor.

D. Stern, M. DiGiovanna, 1995, Cancer research.

Drugs targeting insulin-like growth factor 1 receptor

M. DiGiovanna, T. Mayer, L. Harris, 2009 .

Molecular marker expression in oral and oropharyngeal squamous cell carcinoma.

B. Haffty, D. Carter, B. Smith, 2001, Archives of otolaryngology--head & neck surgery.

Cytotoxicity and DNA crosslinks produced by mitomycin analogs in aerobic and hypoxic EMT6 cells.

S. Keyes, S. Rockwell, A. Sartorelli, 1991, Cancer communications.

Sirolimus and trastuzumab combination therapy for HER2-positive metastatic breast cancer after progression on prior trastuzumab therapy

L. Harris, D. Zelterman, C. Hatzis, 2015, Breast Cancer Research and Treatment.

Trastuzumab Emtansine for Residual Invasive HER2‐Positive Breast Cancer

P. Fasching, A. Schneeweiss, Chiun-Sheng Huang, 2019, The New England journal of medicine.

Adjuvant T-DM1 versus Trastuzumab in Patients with Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer: Subgroup Analyses from KATHERINE.

C. Geyer, N. Wolmark, S. Loibl, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

Carpal tunnel syndrome associated with the use of aromatase inhibitors in breast cancer.

G. Chung, M. DiGiovanna, Jaehyuk Choi, 2008, Clinical breast cancer.

Phosphorylation sensitivity of the commonly used anti-p185neu/erbB2 monoclonal antibody clone 3B5 suggests selective usage of autophosphorylation sites.

M. DiGiovanna, 1997, Analytical biochemistry.

Abstract P6-06-37: Predicting improvements in survival based on improvements in pathologic response rate to neoadjuvant chemotherapy in different breast cancer subtypes

L. Pusztai, W. Symmans, C. Hatzis, 2013 .

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

S. Loi, G. Hortobagyi, L. Carey, 2022, JAMA oncology.

Differentiation stage specificity of tyrosine phosphorylation in response to granulocyte macrophage colony stimulating factor (GM-CSF).

A. Sartorelli, M. DiGiovanna, 1992, Cancer letters.

Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.

A. Chakraborty, K. Liang, M. DiGiovanna, 2008, Cancer research.

Adenoid cystic carcinoma: A retrospective clinical review

D. Ross, B. Haffty, D. Carter, 2001, International journal of cancer.

The impact of communication style on patient satisfaction

L. Pusztai, C. Hatzis, A. Chagpar, 2019, Breast Cancer Research and Treatment.

Co-targeting the HER and IGF/insulin receptor axis in breast cancer, with triple targeting with endocrine therapy for hormone-sensitive disease

C. Hatzis, A. Chakraborty, M. DiGiovanna, 2017, Breast Cancer Research and Treatment.

In vitro and in vivo studies of the combination of IGF1R inhibitor figitumumab (CP-751,871) with HER2 inhibitors trastuzumab and neratinib

A. Chakraborty, M. DiGiovanna, C. Zerillo, 2015, Breast Cancer Research and Treatment.

Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial

E. Winer, S. Loi, L. Carey, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Acquired resistance to HER2-targeted therapies creates vulnerability to ATP synthase inhibition.

D. Rimm, Zongzhi Z. Liu, D. Stern, 2019, Cancer research.

Activation (tyrosine phosphorylation) of ErbB-2 (HER-2/neu): a study of incidence and correlation with outcome in breast cancer.

C. Benz, A. Thor, D. Stern, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Association of constitutively activated hepatocyte growth factor receptor (Met) with resistance to a dual EGFR/Her2 inhibitor in non-small-cell lung cancer cells

S. Agarwal, L. Harris, D. Rimm, 2009, British Journal of Cancer.

Pathobiologic findings in DCIS of the breast: morphologic features, angiogenesis, HER-2/neu and hormone receptors.

C. Howe, P. Chu, D. Stern, 2001, Experimental and molecular pathology.

Patient preferences regarding incidental genomic findings discovered during tumor profiling

L. Pusztai, Gang Han, G. Chung, 2016, Cancer.

Neoadjuvant weekly nab-paclitaxel (wA), carboplatin (Cb) plus bevacizumab (B) with or without dose-dense doxorubicin-cyclophosphamide (ddAC) plus B in ER+/HER2-negative (HR+) and triple-negative (TN) breast cancer (BrCa): A BrUOG study.

L. Harris, V. Bossuyt, G. Chung, 2012 .

Abstract P5-13-02: Neoadjuvant aromatase inhibitor therapy plus the mTOR inhibitor everolimus in postmenopausal women with hormone receptor positive/HER2 negative breast cancer and an oncotype Dx recurrence score (≤25)

D. Zelterman, C. Hatzis, G. Chung, 2020 .

Impacts of Early Guideline-Directed 21-Gene Recurrence Score Testing on Adjuvant Therapy Decision Making.

L. Pusztai, C. Hatzis, G. Chung, 2017, Journal of oncology practice.

Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer

L. Pusztai, V. Bossuyt, C. Hatzis, 2015, Breast Cancer Research and Treatment.

Synergistic Interactions between Tamoxifen and Trastuzumab (Herceptin)

Athanassios Argiris, A. Argiris, S. Whalen, 2004, Clinical Cancer Research.

Influence of activation state of ErbB-2 (HER-2) on response to adjuvant cyclophosphamide, doxorubicin, and fluorouracil for stage II, node-positive breast cancer: study 8541 from the Cancer and Leukemia Group B.

D. Berry, L. Norton, L. Dressler, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Breast sentinel lymph node dissection before preoperative chemotherapy.

J. Weidhaas, L. Harris, L. Philpotts, 2008, Archives of surgery.

Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers.

L. Pusztai, J. Foldi, M. DiGiovanna, 2019, The Lancet. Oncology.

Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+ metastatic breast cancer with brain metastases (HER2CLIMB).

E. Winer, S. Loi, L. Carey, 2020 .

Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma.

Benjamin D. Smith, B. Haffty, D. Carter, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Relationship of epidermal growth factor receptor expression to ErbB-2 signaling activity and prognosis in breast cancer patients.

A. Thor, D. Stern, S. Whalen, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations

L. Harris, M. DiGiovanna, C. Zerillo, 2010, Breast Cancer Research.

Phosphorylated/Activated HER2 as a Marker of Clinical Resistance to Single Agent Taxane Chemotherapy for Metastatic Breast Cancer

C. Hudis, L. Norton, C. Moskowitz, 2005, Cancer investigation.

Sequence of radiotherapy with tamoxifen in conservatively managed breast cancer does not affect local relapse rates.

B. Haffty, B. Burtness, M. DiGiovanna, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Use of neoadjuvant chemotherapy for patients with stage I to III breast cancer in the United States

C. Gross, L. Pusztai, A. Chagpar, 2015, Cancer.

Production of Antibodies That Recognize Specific Tyrosine‐Phosphorylated Peptides

D. Stern, M. DiGiovanna, R. Roussel, 2000, Current protocols in molecular biology.

Bidirectional Text Messaging to Monitor Endocrine Therapy Adherence and Patient-Reported Outcomes in Breast Cancer.

C. Gross, L. Pusztai, Gang Han, 2017, JCO clinical cancer informatics.

Self-management and transitions in women with advanced breast cancer.

Elizabeth H Bradley, Ruth McCorkle, H. Prigerson, 2011, Journal of pain and symptom management.

Five-Year Update of an Expanded Phase II Study of Dose-Dense and -Intense Doxorubicin, Paclitaxel and Cyclophosphamide (ATC) in High-Risk Breast Cancer

M. Reiss, D. Zelterman, G. Chung, 2005, Oncology.

Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines

Michael P. DiGiovanna, A. Chakraborty, M. DiGiovanna, 2010, Breast Cancer Research and Treatment.

Active signaling by Neu in transgenic mice

R. Cardiff, R. Coffey, D. Stern, 1998, Oncogene.

Functional assay for HER-2/neu demonstrates active signalling in a minority of HER-2/neu-overexpressing invasive human breast tumours.

D. Stern, M. DiGiovanna, S. Flynn, 1996, British Journal of Cancer.

Cost-Effectiveness of Neoadjuvant-Adjuvant Treatment Strategies for Women With ERBB2 (HER2)–Positive Breast Cancer

L. Pusztai, M. DiGiovanna, K. Adelson, 2020, JAMA network open.

Systematic approach to providing breast cancer survivors with survivorship care plans: a feasibility study.

L. Pusztai, G. Chung, A. Chagpar, 2015, Journal of oncology practice.

Preoperative Chemotherapy Decreases the Need for Re-Excision of Breast Cancers Between 2 and 4 cm Diameter

J. Weidhaas, L. Harris, G. Chung, 2009, Annals of Surgical Oncology.

Phase 1b study of the mammalian target of rapamycin inhibitor sirolimus in combination with nanoparticle albumin–bound paclitaxel in patients with advanced solid tumors

L. Harris, D. Zelterman, S. Gettinger, 2015, Cancer.

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I–III HER2-positive breast cancer

L. Pusztai, C. Hatzis, A. Chagpar, 2018, Breast Cancer Research and Treatment.

Phase I study of the HDAC inhibitor vorinostat in combination with capecitabine in a biweekly schedule in advanced breast cancer.

L. Pusztai, G. Israel, L. Harris, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Extracting Functional Information From Tissues

M. DiGiovanna, 2001, Molecular Diagnosis.

Combinations of HER2, estrogen receptor (ER) and IGF-I receptor (IGF1R) inhibitors induce apoptosis in breast cancer cells: Dramatic effects of HER2 inhibitors on non-overexpressing cells

A. Chakraborty, M. DiGiovanna, 2006 .

Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.

A. Chakraborty, K. Liang, M. DiGiovanna, 2008, Cancer research.